Although they initially responded favorably, EGFR-mutated NSCLC patients eventually acquire resistance to EGFR-TKI in 8–16 months after first-line targeted drug therapy (Rotow and Bivona, 2017). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.